High-dose infliximab prophylaxis in endotoxin-induced uveitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 4, 2007, Pages 343-350

  Diaz Llopis, Manuel ^a,b   García Delpech, Salvador ^b   Salom, David ^a   Udaondo, Patricia ^a   Bosch Morell, Francisco ^b,c   Quijada, Arturo ^b   Romero, Francisco J ^b,c   Amselem, Luis ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b Fundacion Oftalmologica del Mediterraneo   (Spain)

^c UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; ENDOTOXIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; EYE PROTEIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; NONHUMAN; RABBIT; SALMONELLA TYPHIMURIUM; UVEITIS; ANIMAL; ANTERIOR EYE CHAMBER; CILIARY BODY; DISEASE MODEL; DRUG EFFECT; EXUDATE; INTRAVENOUS DRUG ADMINISTRATION; IRIDOCYCLITIS; IRIS; METABOLISM; PATHOLOGY; RANDOMIZATION;

ANIMALS; ANTERIOR CHAMBER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; CILIARY BODY; DISEASE MODELS, ANIMAL; ENDOTOXINS; EXUDATES AND TRANSUDATES; EYE PROTEINS; INJECTIONS, INTRAVENOUS; IRIS; LIPOPOLYSACCHARIDES; RABBITS; RANDOM ALLOCATION; SALMONELLA TYPHIMURIUM; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, ANTERIOR;

EID: 35848969541     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.0148     Document Type: Article

References (25)

1. Smith, J.R., Hart, P.H., and Williams, K.A. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol. Cell. Biol. 76: 497-512, 1998.
2. Howes, E.L., Cole, P.W., Adair, T.M., et al. Cellular and vascular responses in acute experimental ocular inflammation. Invest. Ophthalmol. Vis. Sci. 35:4031-4038, 1994.
3. Fleisher, L.N., Ferrell, J.B., Smith, M.G., et al. Lipid mediators of tumor necrosis factor alpha induced uveitis. Invest. Ophthalmol. Vis. Sci. 32:2393-2399, 1991.
4. De Vos, A.F., Hoekzema, R., and Kijlstra, A. Cytokines and uveitis. A review. Curr. Eye Res. 6:581-597, 1992.
5. Yoshida, M., Yoshimura, N., Hangai, M., et al. Interleukin 1 gamma, interleukin 1 beta, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 35:1107-1113, 1994.
6. De Vos, A.F., Van Haren, M.A.C., Verhagen, C., et al. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in rats. Invest. Ophthalmol. Vis. Sci. 35:1100-1106, 1994.
7. Rosenbaum, J.T., Samples, J.R., Hefeneider, S.H., et al. Ocular inflammatory effects of intravitreally injected tumor necrosis factor. Am. J. Pathol. 133:47-53, 1988.
8. Mo, J.S., Matsukawa, A., Ohkawara, S., et al. Involvement of TNF alpha, IL-1 beta, and IL-1 receptor antagonist in LPS-induced rabbit uveitis. Exp. Eye Res. 66:547-557, 1998.
9. Santos Lacomba, M., Marcos Martin, C., Gallardo Galera, J.M., et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 33:251-255, 2001.
10. Suhler, E.B., Smith, J.R., Wertheim, M.S., et al. A prospective trial of infliximab therapy for refractory uveitis. Arch. Ophthalmol. 123:903-912, 2005.
11. Benitez del Castillo, J.M., Martinez de la Casa, J.M., Pato Cour, E. et al. Long-term treatment of refractory posterior uveitis with anti-TNF alpha (infliximab). Eye 19:841-845, 2005.
12. Kahn, P., Weiss, M., Imundo, L.F., et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113:860-864, 2006.
13. Hoekzema, R., Verhagen, C., Van Haren, M.A.C., et al. Endotoxin-induced uveitis in rat: The significance of intraocular interleukin 6. Invest. Ophthalmol. Vis. Sci. 33:88-95, 1992.
14. Foster, C.S., Tufail, F., Waheed, N.K., et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch. Ophthalmol. 121(4):437-440, 2003.
15. Guignard, S., Gossec, L., Salliot, C., et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondilarthropathy: A retrospective study. Ann. Rheum. Dis. 65(12):1631-1634, 2006.
16. Koizumi, K., Poulakis, V., Doehmen, S., et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest. Ophthalmol. Vis. Sci. 44:2184-2191, 2003.
17. Avunduk, M.C., Avunduk, A.M., Oztekin, E., et al. Etanercept treatment in the endotoxin-induced uveitis of rats. Exp. Eye Res. 79:357-365, 2004.
18. Rosenbaum, J.T., and Boney, R.S. Failure to inhibit endotoxin-induced uveitis with antibodies that neutralize tumor necrosis factor. Reg. Immnunol. 5:299-303, 1993.
19. Kasner, L., Chan, C.C., Whitcup, S.M., et al. The paradoxical effect of tumor necrosis factor (TNF-alpha) in endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 34:2911-2917, 1993.
20. de Vos, A.F., Van Haren, M.C., Verhagen, C., et al. Systemic antitumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp. Eye Res. 61:667-675, 1995.
21. Barbara, J.A.J., Van Ostade, X., and Lopez, A.F. Tumor necrosis factor-alpha (TNF-alpha): The good, the bad, and potentially very effective. Immunol. Cell. Biol. 74:434-443, 1996.
22. Bhattacherjee, P., and Parke, A. The reduction of inflammatory responses in lipopolysaccharide-tolerant eyes. Am. J. Pathol. 122:268-276, 1986.
23. Brito, B.E., Marcano, J.C., Salazar, E., et al. Age as a determinant factor for endotoxin induced uveitis. Ocul. Immunol. Inflamm. 14:117-124, 2006.
24. De Vos, A.F., Van Haren, M.A.C., Verhagen, C., et al. TNF-induced uveitis in the Lewis rat is associated with interleukin 6 production. Exp. Eye Res. 35:199-207, 1995.
25. Murphy, C.C., Ayliffe, W.H., Booth, A., et al. Tumor necrosis factor-alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111:352-356, 2004.